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BALR-6 regulates cell growth and cell
survival in B-lymphoblastic leukemia
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Jayanth Kumar Palanichamy1,7, Tiffany M. Tran1, Jaime Anguiano1, Michael J. Davoren5,6, Michael O. Alberti1,
Kimanh T. Pioli1, Salemiz Sandoval1, Gay M. Crooks1,2,3,4 and Dinesh S. Rao1,2,3,4*
Abstract
Background: A new class of non-coding RNAs, known as long non-coding RNAs (lncRNAs), has been recently described.
These lncRNAs are implicated to play pivotal roles in various molecular processes, including development and oncogenesis.
Gene expression profiling of human B-ALL samples showed differential lncRNA expression in samples with particular
cytogenetic abnormalities. One of the most promising lncRNAs identified, designated B-ALL associated long RNA-6
(BALR-6), had the highest expression in patient samples carrying the MLL rearrangement, and is the focus of this study.
Results: Here, we performed a series of experiments to define the function of BALR-6, including several novel splice forms
that we identified. Functionally, siRNA-mediated knockdown of BALR-6 in human B-ALL cell lines caused reduced cell
proliferation and increased cell death. Conversely, overexpression of BALR-6 isoforms in both human and mouse cell lines
caused increased proliferation and decreased apoptosis. Overexpression of BALR-6 in murine bone marrow transplantation
experiments caused a significant increase in early hematopoietic progenitor populations, suggesting that its
dysregulation may cause developmental changes. Notably, the knockdown of BALR-6 resulted in global
dysregulation of gene expression. The gene set was enriched for leukemia-associated genes, as well as for the
transcriptome regulated by Specificity Protein 1 (SP1). We confirmed changes in the expression of SP1, as well
as its known interactor and downstream target CREB1. Luciferase reporter assays demonstrated an
enhancement of SP1-mediated transcription in the presence of BALR-6. These data provide a putative mechanism for
regulation by BALR-6 in B-ALL.
Conclusions: Our findings support a role for the novel lncRNA BALR-6 in promoting cell survival in B-ALL. Furthermore,
this lncRNA influences gene expression in B-ALL in a manner consistent with a function in transcriptional regulation.
Specifically, our findings suggest that BALR-6 expression regulates the transcriptome downstream of SP1, and that this
may underlie the function of BALR-6 in B-ALL.
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Background
The human genome produces thousands of non-coding
transcripts [1]. These include the recently described class
of long non-coding RNAs (lncRNAs), which have distinct
chromatin signatures and epigenetic marks, designating
them as unique structures that are conserved in mammals
[2, 3]. More recently, comparison of lncRNA expression
in zebrafish to that of mammals has suggested that
although these structures retain limited overall sequence
conservation among vertebrates, they show strong conser-
vation of short stretches of sequence, chromosomal syn-
teny and functional conservation [4]. Prior studies have
shown that lncRNAs play a variety of roles in the regula-
tion of transcription, splicing and miRNA function [5–7].
This may not be an exhaustive description of the functions
of lncRNAs, as new functions are being discovered in
other cellular processes [8, 9]. As might be expected, con-
sidering their roles in critical cellular functions, lncRNAs
have been found to be dysregulated in cancer, with
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functional roles in oncogenesis described for a handful of
lncRNAs so far [10–13].
B-lymphoblastic leukemia (B-acute lymphoblastic
leukemia, B-ALL) is a malignancy of precursor B-cells har-
boring mutations and translocations that result in dysregu-
lated gene expression [14, 15]. We have recently completed
a comprehensive description of lncRNAs in B-ALL and
analyzed the association of lncRNA expression with clini-
copathologic parameters. Our study showed differential
lncRNA expression in samples with particular cytogenetic
abnormalities [16]. One of the lncRNAs from our study,
designated B-ALL associated long RNA-6 (BALR-6), was
significantly upregulated in all subsets of patient samples
when compared to normal CD19+ cells. Interestingly, the
highest expression of BALR-6 was seen in patient samples
carrying the MLL rearrangement [16]. MLL rearranged B-
ALL cases have a very poor prognosis and occur in infants,
making them particularly hard to treat [17].
Located on chromosome 3p24.3 in humans, BALR-6 ex-
ists in a syntenic gene block with neighboring genes SATB1
and TBC1D5 that is conserved in several vertebrate species
(Fig. 1a, b and d) [16]. Analysis of publically available data
from the Broad Institute/ENCODE shows H3K4m3 and
H3K36m3 modifications along the promoter and gene
body at LOC339862, where BALR-6 resides, indicating that
it is a transcriptional element (Fig. 1a) [4, 16, 18–20]. Alter-
native splicing analysis by the Swiss Institute of Bioinfor-
matics predicted multiple transcripts expressed at this gene
locus (Additional file 1: Figure S1A) [21]. Moreover, 100
Vertebrate PhastCons analyses of the BALR-6 locus
demonstrated significant conservation of the gene body,
suggesting a functional transcript (Fig. 1b) [22].
To further study this lncRNA we undertook loss-of-
function analyses in B-ALL cell lines and gain-of-
function analyses in vivo. We found that BALR-6 is a
pro-survival factor for B-ALL cell lines, and that its
knockdown led to decreased growth and increased apop-
tosis of these cells. In vivo, overexpression of BALR-6
led to an alteration of hematopoiesis with a shift to more
immature progenitor populations. Gene expression ana-
lyses of knockdown cell lines showed a differentially
expressed gene set in BALR-6 knockdown cells, with en-
richment for SP1 transcriptional targets and leukemogenic
genes. Finally, luciferase assays demonstrated an increase
in transcriptional activity when SP1 and BALR-6 were co-
expressed. Together, these findings point to a role for
BALR-6 in cellular survival, leukemogenesis and highlight
the role of novel elements of gene regulation in B-ALL.
Results
BALR-6 knockdown inhibits proliferation of human B-ALL
cell lines
To comprehensively study the function for this novel
lncRNA, we first characterized the transcripts originating
at the genomic locus corresponding to BALR-6. Using
RS4;11 cell line mRNA, Rapid Amplification of cDNA
Ends (RACE) uncovered multiple isoforms; from these,
three were cloned and sequenced corresponding to the
genomic locus as shown (Additional file 1: Figure S1A-B).
Northern Blot analysis of RS4;11 DNAse treated RNA re-
vealed the expression of two isoforms containing exon 3
and exon 5 sequences, one sized at ~3.8 Kb and the other
at ~1.2 Kb (Additional file 1: Figure S1C). The annotated
mRNA and new alternative splice forms, including unan-
notated exons, were confirmed as depicted in Fig. 1c.
Isoform 1 contains several small open reading frames
(ORFs), however no Kozak sequences are found in their
initial ATG region, and the predicted ORFs do not
resemble any known functional proteins or peptide
[23]. Isoforms 2 and 3 lacked open reading frames
and translation initiation sites as evaluated by EMBOSS
Transeq, predicting them to be non-coding transcripts
(Additional file 1: Figure S1D).
To map the murine homologous transcript, we carried
out 5′RACE and 3′RACE using mRNA extracted from
murine pre B-ALL cell line 70Z/3. The sequences uncov-
ered matched the human BALR-6 sequence, confirming
that there is a murine transcript originating from this same
locus (Additional file 1: Figure S1E). Further analysis by
BLAT showed genomic conservation of syntenic blocks
in a variety of vertebrates, including Xenopus tropicalis
(Fig. 1d). Together, these data demonstrate a highly
conserved, functional and complex gene locus that ex-
presses multiple non-coding transcripts, some yet to be
discovered. During normal B cell development, BALR-6
is dynamically expressed, with high expression in pre-B
cells and subsequent downregulation (Fig. 2a). This
suggests that the high expression of BALR-6 in B-ALL
could represent a stage-specific expression pattern in
leukemia derived from early stages of B-cell develop-
ment. To elucidate a cellular function for BALR-6, we
first evaluated the expression levels of the transcripts in
human B-ALL cell lines. BALR-6 expression was high-
est in RS4;11 cells and MV(411) cells, which carry the
MLL-AF4 rearrangement, when compared to other
lines (Fig. 2b). Additionally, RS4;11 cells treated with
bromodomain and extra-terminal (BET) motif binding
protein inhibitor I-BET151 [24] showed decreased levels
of BALR-6 in a dose-dependent manner (Fig. 2c). Given
that I-BET151 has previously been shown to inhibit tran-
scription downstream of MLL, we propose that BALR-6
expression is induced by MLL, although this effect may
not be entirely specific to MLL-AF4.
Using the approach described previously, siRNAs
against the splice junctions between exons of BALR-6
were cloned into a mmu-miR-155 expression cassette
(Additional file 1: Figure S2A) [4, 16, 25, 26]. We ob-
served knockdown of all the identified transcripts in
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multiple B-ALL cell lines (Fig. 2d and Additional file 1:
Figure S2B). Transduced B-ALL cells showed a reduction
in proliferation as early as 48 h after plating, with consist-
ent reduction in proliferation observed over the full dur-
ation of the assay (up to 144 h) (Fig. 2e, f and Additional
file 1: Figure S2C). siRNA-transduced B-ALL cells had sig-
nificantly higher levels of apoptosis, as measured by
AnnexinV, when compared with vector-transduced lines
(Fig. 2g, h and Additional file 1: Figure S2D). Flow cytome-
try demonstrated that the siRNA2-transduced RS4;11 cell
lines had an increase in Sub-G0 cells and a decrease in all
other cell stages, consistent with increased apoptosis and
decreased flux through the cell cycle (Fig. 2i). Together,
these findings suggest a modest yet conserved role for
BALR-6 in the regulation of B-ALL cell survival and
proliferation.
Constitutively expressed BALR-6 supports cell survival
and proliferation
To examine the effects of BALR-6 gain of function, we
overexpressed the previously identified isoforms in the
human B-ALL cell line Nalm-6, which has relatively low
Fig. 1 Molecular characterization of BALR-6. a Top: Chromosomal location of BALR-6 in the human genome, surrounding genes, qPCR primers,
siRNAs, known annotated exons (green boxes), known introns (black lines) are shown. Bottom: Chip-Seq histone modification map from the Broad
institute/ENCODE, taken from UCSC genome browser, shows H3K4m3 and H3K36m3 patterns at LOC339862 in four different cell types indicating
active transcription of the lncRNA. b The 100 Vertebrate PhastCons plot from the UCSC whole-genome shows conserved regions among 98 vertebrates
including mice and zebrafish throughout the locus. c RACE discovered unannotated exons (magenta) depicted with known annotated exons (green) at
LOC339862. d Schematic depicting genomic conservation of the syntenic block among multiple vertebrates, as analyzed by BLAT. Grey box
indicates location of homology to BALR-6
Rodríguez-Malavé et al. Molecular Cancer  (2015) 14:214 Page 3 of 15
endogenous levels of the transcript (Figs. 2b and 3a).
Gene transfer was conducted via a lentiviral expression
system that has proven successful in our previous
studies (Additional file 1: Figure S2E) [16]. Constitutive
overexpression of BALR-6 Isoforms 2 and 3 led to a sig-
nificant increase in proliferation as measured by MTS
(Fig. 3c). In addition to an observed increase in overall
growth rate, BALR-6 Isoforms 2 and 3 caused an increase
in S phase cells and G2-M cells (Fig. 3d). Furthermore,
AnnexinV staining showed significantly lower numbers of
apoptotic cells under basal growth conditions in cell lines
overexpressing any of the BALR-6 isoforms (Additional
file 1: Figure S2G).
To overexpress BALR-6 in mouse cells, we con-
structed a set of MSCV-based bicistronic vectors (Fig. 3b,
Additional file 1: Figure S2F). Successful overexpression
of these constructs in murine pre B-ALL 70Z/3 cells led
to a modest increase in proliferation (Fig. 3e and f). Cell
cycle analysis of these lines showed an increase of S
phase cells, G2-M cells (in Isoform 3 overexpressing lines)
and a reduction in Sub-G0 cells, similar to the effects in
Nalm-6 cells (Fig. 3g and h). Analysis by AnnexinV staining
confirmed the lower number of apoptotic cells in Isoform 3
expressing cell lines (Additional file 1: Figure S2H). More-
over, these 70Z/3 Isoform 3 overexpression lines were less
vulnerable to prednisolone-induced apoptosis (Additional
file 1: Figure S2I). Conversely, siRNA-transduced RS4;11
cells were more prone to prednisolone-induced apoptosis
(Additional file 1: Figure S2I). Therefore, knockdown and
overexpression of BALR-6 had opposing phenotypes
in B-ALL cell lines, and gain-of-function phenotypes
were conserved in both human and mouse cells.
Enforced BALR-6 expression promotes expansion of
hematopoietic progenitor populations in vivo
Since BALR-6 is highly expressed in B-ALL, we tested
the effects of constitutive expression in an in vivo model
[16]. 5-FU enriched bone marrow was transduced with
retrovirus expressing the BALR-6 Isoform 3 and trans-
planted into lethally irradiated hosts (Fig. 3 and Additional
file 1: Figure S2F, 2H). Mice were followed with peripheral
bleeds for 16 weeks and then sacrificed for analysis.
Peripheral white blood cell counts were not statisti-
cally different between the control and experimental
groups. However, mice with enforced expression of
BALR-6 showed a trend towards lower red blood cell
counts, hematocrit and platelet counts (Additional file 1:
Figure S3A). Flow cytometry revealed a lower percentage
of CD11b + myeloid cells and a higher percentage of
B220+ B-cells, but no difference in CD3ε + T-cell per-
centage in the eGFP+ population of experimental mice
(Additional file 1: Figure S3B-C).
Mice were sacrificed following 4 months of reconstitu-
tion. Gross analysis showed no changes in the thymus,
spleen, livers or kidneys. Microscopic inspection of
hematoxylin and eosin – stained tissues did not reveal
any differences (Additional file 1: Figure S3D). In the
bone marrow, qRT-PCR confirmed successful overex-
pression of BALR-6 (Additional file 1: Figure S4A-B).
Analysis by flow cytometry revealed an increase in pre-
cursor cell populations in the eGFP+ population of the
experimental mice, when compared to the control group
(Fig. 4a and b, Additional file 1: Figure S5C). After ex-
clusion of differentiated cells in the bone marrow, we
observed increased relative proportion of Lin-Sca1 + c-
Kit + (LSK) cells, hematopoietic stem cells (HSCs) and
lymphoid-primed multipotent progenitors (LMPPs) in
mice overexpressing BALR-6 (Fig. 4a and b). An increase
in the relative population of Lin-Sca1loc-Kitlo cells and a
trend towards increased relative population of common
lymphoid progenitors (CLPs) was also observed (Additional
file 1: Figure S4C). The developmental pathway of B-cells
in the bone marrow was investigated by the method of
Hardy et al. [27]. Once again, trends towards higher relative
proportions of these B-cell developmental stages were ob-
served (fractions A-F, Additional file 1: Figure S4D). Taken
together, these results suggest that BALR-6 overexpression
leads to an enrichment of early developmental stage cells
in murine bone marrow, indicating that its expression
confers a survival advantage or increased proliferation
for cells in these earlier stages.
BALR-6 regulates expression of genes involved in
multiple biological processes
At the molecular level, several studies have demon-
strated that many lncRNAs act as transcriptional regula-
tors [5, 11, 23, 28, 29]. To explore whether or not
BALR-6 regulates gene expression, RNA isolated from
knockdown cell lines was analyzed by microarray [30,
31]. Upon siRNA mediated knockdown of BALR-6, 2499
probes showed differential expression. Of these, 1862
unambiguously mapped to 1608 unique Entrez Gene IDs.
Unsupervised hierarchical clustering analysis identified
differentially expressed genes in the siRNA-expressing cell
lines (Fig. 5a).
Further data analysis was carried out using WebGES-
TALT [32, 33]. Gene Ontology (GO) slim classification
of differentially expressed genes by molecular function
was utilized to provide insight into the pathways in
which BALR-6 is involved, with protein binding function
category having the most dysregulated genes (Fig. 5b). A
number of biological processes, as annotated in the GO
database, were significantly dysregulated in BALR-6
knockdown cell lines, including cell death and cell pro-
liferation (Fig. 5c). Disease associated enrichment ana-
lysis, which was inferred using GLAD4U, showed an
enrichment of genes known to be dysregulated in various
disease states (Fig. 5e). Of the 38 significantly associated
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disease states, 14 were of leukemic origin. Transcription
factor enrichment analysis showed a significant enrich-
ment of genes that are predicted targets of SP1, among
other transcription factors (Fig. 5d). Taken together, these
data revealed the biological importance of BALR-6. A de-
tailed description of the microarray analyses can be found
in the methods.
SP1 transcriptome is modulated by BALR-6
As indicated by the transcription factor enrichment ana-
lysis, we confirmed that the expression SP1 and CREB1,
a target and interactor of SP1, were dysregulated upon
BALR-6 knockdown (Fig. 6a). The strongest phenotype
was seen in the siRNA2-mediated knockdown, which
also showed the strongest cellular phenotypes in the
majority of pre B-ALL cell lines (Figs. 2d, i and 6a,
Additional file 1: Figure S2B-D and Figure S5A-B).
Conversely, increased levels of SP1 and CREB1 correlated
with overexpression of BALR-6 isoforms in both human
and murine cell lines (Nalm-6 and 70Z/3) (Fig. 6b).
To confirm our findings, a second microarray analysis
was carried out with technical duplicates of RS4;11 cell
lines transduced with empty vector or siRNA2. 2756
probes showed differential expression. Of these, 2280
unambiguously mapped to 2128 Entrez Gene IDs and
were analyzed by hierarchical clustering (Additional file 1:
Figure S6A). Enrichment analysis in WebGESTALT re-
vealed similar GO slim classifications (Additional file 1:
Figure S6B-C), and transcription factor target enrich-
ment analysis confirmed the significant enrichment of
SP1 targets seen previously (Fig. 5d, Additional file 1:
Figure S6D). Additionally, enrichment of CREB1 tar-
gets was significant (Additional file 1: Figure S6D).
Notably, leukemic diseases were the only ones signifi-
cantly enriched in the disease association analysis
(Additional file 1: Figure S6E). Together, these findings in-
dicated a consistent change in the transcriptome, particu-
larly downstream of SP1, upon knockdown of BALR-6 in
MLL rearranged B-ALL.
To further understand the relationship of BALR-6 and
SP1, we examined promoter regions of known SP1 tar-
gets (CREB1 and p21) and cloned these sequences into
the luciferase reporter vector, pGL4.11 (Fig. 6c). The
CREB1 promoter contained 7 putative SP1 binding sites,
while the p21 promoter contained 6 such sites (Additional
file 1: Figure S5C-D). Luciferase reporter assays in HEK
293 T cells with constitutive expression of SP1, Isoform 1,
Isoform 3 or a combination of these vectors, revealed in-
creased luciferase activity in both promoters (Fig. 6d and e).
Notably, when SP1 and BALR-6 were co-overexpressed, we
noted a strong increase in transcriptional activity with both
the CREB1 and p21 promoter.
Discussion
The discovery of lncRNAs has revolutionized how we
think about gene expression. The genomic organization
of many lncRNAs is indeed complex. Some are found in
regions overlapping with protein coding genes, while
others that are exclusively intergenic [2, 4]. Some lncRNAs
contain microRNAs within either their exonic or intronic
sequence [34, 35]. Here, we have characterized several iso-
forms of a lncRNA that is overexpressed in leukemia and
shows dynamic expression in hematopoietic development
[16]. Expressed from a locus adjacent to genes important
in lymphocyte development, BALR-6 itself is dynamically
regulated during human B-cell development [36–38].
Our work significantly adds to the known repertoire
of RNA molecules that are expressed from this locus,
and several of these appear to be functional within a
cellular context.
In this manuscript, we describe the cellular function of
a second lncRNA that was discovered as being overex-
pressed in MLL-translocated B-ALL. In some ways,
BALR-6 shows some similarities with the other lncRNA
we studied, BALR-2 [16]. Indeed, knockdown of both
lncRNAs led to decreased cell growth and increased
apoptosis, and overexpression led to increased growth
and a partial resistance to prednisolone treatment. These
findings are not altogether surprising given that these
lncRNAs may be contributing to the poor clinical behavior
of an aggressive cytogenetic subtype of B-ALL [17].
However, there are important differences between these
lncRNAs—the genomic locus for BALR-6 is more com-
plex, there are multiple isoforms and no comparable
murine transcript is described in publically available da-
tabases. Nonetheless, we have obtained fragments of a
(See figure on previous page.)
Fig. 2 BALR-6 knockdown reduces cell proliferation and increases apoptosis in human B-ALL cells. a BALR-6 expression in human bone marrow
B-cell subsets by qRT-PCR. Normalized to ACTIN. b Quantitation of BALR-6 expression in human B-ALL cell lines by qRT-PCR confirming elevated
levels in MLL translocated cell lines RS4;11, and MV(411). Normalized to ACTIN. c RS4;11 cell lines treated with 1 μM, and 2 μM of I-BET151 inhibitor for
36 h, presented a decrease in BALR-6 expression levels. Normalized to ACTIN. d qRT-PCR quantification of BALR-6 in RS4;11 and Reh cell lines transduced
with vector control, siRNA1 or siRNA2. Normalized to ACTIN. e, f Decreased cell proliferation, upon siRNA mediated knockdown of BALR-6 in RS4;11 cells e,
and Reh cells f as measured by MTS. g, h AnnexinV staining showed that siRNA mediated knockdown of BALR-6 in RS4;11 cells g, and Reh cells h resulted
in an increase of apoptosis. i Propidium iodide staining of RS4;11 knockdown cell lines showed an increase in Sub-G0 and a decrease in
G0-G1, S and G2-M cells. Representative histogram of (i) confirms cell cycle changes by siRNA2, shown to the right. HSC, hematopoietic
stem cell; CLP, common lymphoid progenitor; pro-B, progenitor B; pre-B, precursor B; DMSO, dimethyl sulfoxide. Evaluations were made
using a two-tailed T-test, p < 0.05 (*); p < 0.005 (**); p < 0.0005 (***); p < 0.0001 (****)
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low-expression transcript from murine hematopoietic
cell lines that encoded portions homologous to human
BALR-6. Further characterization of the murine transcripts
will be the goal of future studies.
Significantly, our study is amongst the few character-
izations of lncRNA dysregulation in the hematopoietic
system [16, 39–41]. LncRNAs have been ascribed func-
tions in lymphopoiesis, myelopoiesis and erythropoiesis
[42–45]. Additionally, their differential expression has
been described in peripheral T-cell subsets [46]. Here,
we discovered the effect of BALR-6 overexpression on
early hematopoietic progenitors in the marrow, includ-
ing LSK cells, HSCs and LMPPs. Constitutive expression
of BALR-6 isoforms led to increased survival or prolifer-
ation of normally transient bone marrow progenitor
cells. Furthermore, Hardy fractions showed a trend to-
wards being increased when compared to control, par-
ticularly those that developmentally precede the large
pre B-cell stage (fraction C’, early pre-B). The relative
percentages of more mature B-lineage cells downstream
of these developmental stages are largely normal. Despite
increased proportions of early progenitor cells, passage
through a checkpoint (such as the pre-BCR checkpoint)
may reduce cell numbers back to baseline. This sug-
gests that the function of BALR-6 in vivo may be in
directing differentiation and adequate lymphoid cell
development. The upregulation of this lncRNA causes
a survival or proliferative advantage, a hallmark
of leukemogenesis. Coupling BALR-6 overexpression
with an appropriate oncogenic co-stimulus may lead
to full-blown leukemogenesis or enhancement thereof,
and this is currently an active area of investigation in
the laboratory.
In line with a function in promoting the survival of
early hematopoietic progenitors, BALR-6 clearly affects
proliferation in cell line experiments. Upon siRNA medi-
ated knockdown, we saw reduced cell proliferation and
increased cell death. We observed the opposite effect
when we constitutively expressed BALR-6 in human and
murine B-ALL cell lines. Moreover, similar mechanisms
may be operant in B-ALL with MLL translocations, and
loss-of-function experiments in primary patient samples
and mouse models of MLL-driven leukemia are areas for
further investigation.
Given prior reports of lncRNAs serving to regulate
transcriptional complexes, our finding that BALR-6 knock-
down causes changes in the SP1 transcriptome is compel-
ling. SP1 is a transcriptional regulator that is associated
with dysregulated cell cycle arrest in multiple myeloma
[47–49]. CREB1 is a well-known proto-oncogene that pro-
motes cellular proliferation in hematopoietic cells [50, 51].
Here we demonstrate that SP1-mediated transcription at
the CREB1 and p21 promoters are positively regulated by
BALR-6, providing a putative mechanism for our ob-
servations of BALR-6′s role in B-ALL.
Conclusions
In this study, we demonstrate that the MLL-AF4-
dysregulated lncRNA, BALR-6, plays a role in cell sur-
vival and regulates hematopoietic progenitors. At the
molecular level, BALR-6 regulates the transcriptome of
B-ALL cell lines, likely through regulating SP1-mediated
transcription. In summary, our study has several novel
and unique findings that help uncover a role for a poorly
understood class of molecules in a pathogenetic process.
This will undoubtedly have impacts on our understanding
of molecular biology within cancer cells.
Methods
Cloning and cell culture
mmu-miR-155 formatted siRNAs were cloned into
BamHI and XhoI sites in the pHAGE2-CMV-ZsGreen-
WPRE vector using the strategy that we have previously
described to generate knockdown vectors [16, 25, 26, 52].
Using the sequence information from 5′ and 3′ RACE
products we cloned full length transcripts into an MSCV-
based bicistronic viral vector between the BamHI and
XhoI sites, as described previously and into a pHAGE6-
UBC-ZsGreen-CMV-LNC (P6UZCL) variant of the third
generation lentiviral vector system, between the NotI and
BamHI sites [16, 52]. Primer sequences used are listed in
Additional file 2: Table S1 or mentioned previously [16].
RS4;11 and MV(411), (MLL-AF4-translocated; ATCC
CRL-1873 and CRL-9591), Reh (TEL-AML1-translocated;
CRL-8286), 697 (E2A-PBX1-translocated), Nalm-6, 70Z/3
(ATCC TIB-158) murine pre B-cell leukemic cell line, and
the HEK 293 T cell line (ATCC CRL-11268) were grown
(See figure on previous page.)
Fig. 3 BALR-6 overexpression increases proliferation in human Nalm-6 and murine 70Z/3 cells. a qRT-PCR quantitation of BALR-6 isoform expres-
sion in Nalm-6 human pre B-ALL cell line. Normalized to ACTIN. b qRT-PCR quantification of BALR-6 isoforms in 70Z/3 mouse pre B-ALL cell line.
Normalized to Actin (ISO1) or L32 (ISO3). c Increased cell proliferation in BALR-6 overexpressing Nalm-6 cell lines, as measured by MTS. d Representative
histogram of Nalm-6 overexpression lines, stained with propidium iodide, shows an increase in S phase cells and G2-M cells. e, f Increased cell proliferation
in BALR-6 Isoform 1 (e) and Isoform 3 (f) overexpressing 70Z/3 cell lines, as measured by MTS. g, h Propidium iodide staining of 70Z/3 cells overexpressing
BALR-6 Isoform 1 (g) and Isoform 3 (h), shows a consistent increase in G2-M cells, and a decrease in Sub-G0 cells. Representative histogram of
figures (g-h) confirmed the increase in cells in the G2-M when compared to the empty vector, shown to the right. ISO1, Isoform 1; ISO2, Isoform 2;
ISO3, Isoform 3. Evaluations were made using a two-tailed T-test, p < 0.05 (*); p < 0.005 (**); p < 0.0005 (***); p < 0.0001 (****)
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in their corresponding media at 37 °C in a 5 % CO2
incubator as previously described [16, 53].
Rapid amplification of cDNA ends (RACE)
To determine the 5′ and 3′ transcript ends of the
lncRNAs, we performed RACE using First Choice
RLM-RACE kit (Ambion). Using the sequence infor-
mation from 5′ and 3′ RACE products, we cloned
full length transcripts into P6UZCL, and into the
MSCV viral vector. Primer sequences used and
isoform sequences obtained are listed in Additional file 2:
Table S1.
Fig. 4 BALR-6 overexpression causes an increase in hematopoietic precursor cells in vivo. a Representative FACS plots of hematopoietic progenitor
populations LSK, HSC and LMPP in bone marrow transfer mice. b Quantitation of progenitor populations showing a significant increase in experimental
mice when compared to control. Number of mice used in this analysis: VECTOR, n = 8; ISO3, n = 6. ISO3, Isoform 3; HSC, hematopoietic stem cell; LMPP,
lymphoid primed multipotent progenitor; LSK, lineage- Sca1+ c-Kit+. Evaluations made using a two-tailed T-test, p < 0.05 (*); p < 0.005 (**)
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Transduction and sorting of cell lines
Lentiviruses and MSCV-based retroviruses were pro-
duced to generate knockdown constructs as previously
described [16, 25, 26, 52]. In brief, 5.0 × 105 cells were
spin-infected at 30 °C for 90 min in the presence poly-
brene (4 μg/mL). Transduced cell lines were sorted for
high green expression using a BD FACSAriaII cell sorter,
and analysis was performed using BD FACSDiva software.
Biological assays
For pharmaco-induced assays, cells were cultured at a
concentration of 1.0 × 106 cells per mL and treated for
Fig. 5 BALR-6 knockdown leads to global differential expression of genes. a Unsupervised hierarchical gene clustering of differentially expressed
genes upon BALR-6 siRNA mediated knockdown in RS4;11 cells (PPDE≥ 95 %, fold change≥ 1.5). qRT-PCR confirmation of BALR-6 knockdown
shown below. Normalized to ACTIN. b, c Bar graphs of GO Slim classification enrichment analysis of differentially expressed genes by molecular
function (b), and biological processes (c). d Enrichment analysis of transcription factor targets. Top ten transcription factors with a p-value≤ 0.0001 are
shown. SP1 had the highest number if dysregulated targets, highlighted in light green. For unknown transcription factors, binding site sequence is
shown. e Disease association analysis by GLAD4U, revealing enrichment of genes associated to various malignancies, in particular, hematological
malignancies (dark red). Diseases with a p-value ≤ 0.05 are shown.; PPDE, posterior probability of differential expression. Evaluations were made
using a two-tailed T-test, p < 0.005 (**); p < 0.0005 (***)
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36 h. I-BET151 was dissolved in dimethyl sulfoxide to
desired concentrations. After treatment, cells were har-
vested for RNA extraction. For MTS proliferation assays,
cells were cultured for at least 5 days before plating.
Cells were plated at a density of 2500 cells per 100 μl of
media in each well of a 96 well plate. Reagents were
added according to the manufacturer’s instructions
(Promega CellTiter 96 Aqueous Non-Radioactive Cell
Proliferation Assay kit) and cells were incubated at
37 °C, 5 % CO2 for 4 h before absorbance was measured at
490 nm. For apoptosis assays, cells were plated at 5.0 × 105
cells/mL for 24 h with or without prednisolone treatment.
Prednisolone (TCI America) was dissolved in dimethyl sulf-
oxide to desired concentrations. Cells were harvested after
24 h and stained with APC-tagged AnnexinV. For cell cycle
analysis, cells were synchronized by serum starvation for
12 h (human cell lines) or 4 h (murine cell lines) then
plated at 5.0 × 105 cells/mL and incubated at 37 °C, 5 %
CO2 for 24 h. Cells were harvested, fixed with EtOH and
then stained with propidium iodide. AnnexinV stained
and PI stained samples were analyzed using a BD FACS
HTLSRII flow cytometer and further analysis was
performed using FlowJo.
Luciferase assays
Promoter sequences for CREB1 and p21 were cloned
upstream of synthetic firefly luciferase (luc2p) in the
pGL4.11 vector. Renilla luciferase is expressed in the
pGL4.75 vector downstream of the PGK promoter. HEK
293 T cells were transfected with the pGL4.75 and
pGL4.11 containing reporter vectors at a 1:20 ratio
(5 ng:100 ng), along with a combination of MSCV vector
(empty, Isoform-1 or Isoform-3) and pCMV3 (empty or
SP1-HA, Sino Biological Inc.) vector at a 1:1 ratio
(200 ng:200 ng). For the last condition SP1, Isoform1
and Isoform 3 were transfected together at a ratio of
2:1:1 (200 ng:100 ng:100 ng). Co-transfections were per-
formed with BioT (Bioland Scientific LLC) in 24 well
plates as per the manufacturer’s instructions. Cells were
lysed after 32 h and supernatant lysate was collected as
per manufacturer’s instructions (Promega). The dual lu-
ciferase assay kit (Promega) was used as substrates for
Renilla and firefly luciferase activity. Luminescence was
measured on a Glomax-Multi Jr (Promega). The ratio of
firefly to Renilla luciferase activity was calculated for all
samples. The luminescence for the sample co-transfected
with MSCV empty vector and pCMV3 empty vector, was
used as a normalization control.
qRT-PCR and PCR
RNA from cell lines was reverse transcribed using
qScript (Quantas Biosciences). Real Time quantitative
PCR was performed with the StepOnePlus Real-Time
PCR System (Applied Biosystems) using PerfeCTa SYBR
Green FastMix reagent (Quantas Biosciences). cDNA
from mice samples was amplified using KOD Master
Mix (EMD Millipore) and ran on a 1.2 % agarose gel
stained with ethidium bromide. Primer sequences used
are listed in Additional file 2: Table S1.
Northern blot
Total RNA was separated on a 1.2 % (w/v) formaldehyde
agarose gel and then blotted onto Hybond N+ nylon
membranes (Amersham Biosciences) by semi-dry transfer
(Bio-Rad,
Trans-Blot SD Semi-Dry Transfer Cell). DNA probes
were ordered from Integrated DNA Technologies (IDT,
San Diego, CA) with digoxigenin incorporated at 3′end.
For ACTIN we used the RNA probe provided in the
DIG Northern Starter Kit (Roche). Membranes were
hybridized overnight using ULTRAhyb-Oligo Buffer
(Ambion) at 37 or 42 °C with probes. Visualization was
done by X-Ray film using CDP-Star reagents (Roche).
X-Ray film was scanned and saved as jpeg files. Bright-
ness and contrast was increased by 20 % for ease of
visualization.
Data sources
Human genome assembly GRCh37/hg19 and the mouse
genome assembly GRCm38/mm10 were used. Methyla-
tion patterns for the four cell lines were obtained from
Chip-Seq data available in the UCSC genome browser
generated by the Broad/ENCODE group [18–20]. Peak
viewing range set from 1–50 for H3K4m3 modifications,
and 1–15 for H3K36m3 modifications. Alternative splice
form information was obtained from the Swiss Institute
of Bioinformatics, via UCSC Genome Browser [21].
Genome alignments of RefSeq transcripts from human,
mouse and other vertebrates, GenBank mRNAs and ESTs,
as well as PhastCons scores were obtained from the UCSC
Genome Browser [22].
Microarray data analysis
Microarray data was generated from samples of 3 differ-
ent transduced RS4;11 cell lines with siRNAs against
BALR-6, or the control empty vector. Samples were
hybridized at the UCLA Clinical Microarray Core fa-
cility using Affymetrix HG-U133_Plus_2 microarray.
The Affymetrix raw data files (.cel files) were loaded into
the R program for quality control analysis. Additionally,
raw hybridization intensities were normalized using the
MAS5 method with the affy package in R. Normalized
values were sorted by detection p-value ≤ 0.05. Differential
expression analysis was performed using unpaired Bayesian
comparison model (CyberT Website) [30, 31]. Data was
then sorted for genes with a posterior probability of
deferential expression (PPDE) ≥ 95 % and a fold change ≥
1.5. Analysis of differentially expressed genes was carried
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out using the WEB-based GEne SeT AnaLysis Toolkit
(WebGESTALT, http://bioinfo.vanderbilt.edu/webgestalt/)
[32, 33]. This online tool uses information from different
public data sources for enrichment analysis, including
the Gene Ontology data base, and GLAD4U. A sec-
ond (validation) microarray was carried out, as de-
scribed above, with technical duplicates for RS4;11
cell lines transduced with siRNA2 or the empty vec-
tor. For differential analysis the raw data files were
loaded into the R environment and analyzed using
the R library of Linear Models for Microarray Data
(LIMMA). Pairwise comparison and eBayes fit was carried
out. Data was then sorted for genes with a p-value ≤ 0.05.
Further analysis was done as described above, using
WebGESTALT.
Mice and bone marrow transplantation
Mice were housed under pathogen free conditions at the
University of California, Los Angeles (UCLA). Donor
mice were injected intraperitoneally with 200 mg/kg of
5-fluorouracil. After 5 days the mice were sacrificed. The
bone marrow was collected under sterile conditions and
plated in media enriched with IL-3, IL-6 and mSCF
(Gibco). 24 h after plating, the bone marrow was spin
infected twice, at 30 °C for 90 min in the presence poly-
brene (4 μg/mL), with retroviruses expressing the empty
Fig. 6 SP1 transcriptome is modulated by BALR-6. a Confirmation of SP1 and CREB1 expression in RS4;11 microarray samples, as well as Reh
knockdown cell lines. Normalized to ACTIN. (b) SP1 and CREB1 transcript level increase correlates with overexpression of BALR-6 in Nalm-6 cells
(top) and 70Z/3 cells (bottom). Quantitation by qRT-PCR, normalized to ACTIN (Nalm-6 cells) or L32 (70Z/3 cells). c Schematic depicting location of
cloned promoter sequences in the pGL4.11 vector system for luciferase assays. d Transcriptional activity at CREB1 (left) and p21 (right) promoter
regions upon SP1 and/or BALR-6 overexpression, as measured by luciferase activity. e Quantitation of overexpression in luciferase assays (as seen
in (d)) by qRT-PCR of respective transcripts, normalized to ACTIN. Evaluations were made using a two-tailed T-test, p < 0.05 (*); p < 0.005 (**);
p < 0.0005 (***). luc2p, synthetic firefly luciferase
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MSCV vector or BALR-6 Isoform 3. Recipient mice were
lethally irradiated and injected with donor bone marrow
6 h after irradiation. 8 mice were used per group. One
mouse in the ISO3 group died due to engraftment
failure after 2 weeks post injection. These mice were
bled at 8, 12 and 16 weeks post bone marrow injec-
tion. At 16 weeks the mice were sacrificed for full
analysis. For statistical analysis, one mouse was ex-
cluded due to low eGFP expression. This experiment
was repeated, and had similar results. All animal
studies were approved by the UCLA Animal Research
Committee (ARC).
Flow cytometry of samples
At 16 weeks post bone marrow transplant, blood, bone
marrow, thymus and spleen were collected from the
mice under sterile conditions [53]. Single cell suspen-
sions were lysed in red blood cell lysis buffer. Fluoro-
chrome conjugated antibodies were used for staining
(antibodies were obtained from eBiosciences, and Biole-
gend). Cells were stained with surface marker antibodies
for 30 min at 4 °C, washed twice with 1X PBS, and fi-
nally fixed with 1 % PFA. Flow cytometry was performed
at the UCLA Jonsson Comprehensive Cancer Center
(JCCC) and at the BROAD Stem Cell Research Flow
Core. Analysis was performed using FlowJo software.
The lists of antibodies used and gating schematics are
provided in Additional file 2: Table S2. Normal adult
human bone marrow was obtained commercially from
healthy adults (All Cells, Inc.) as previously described
[51]. CD34 enrichment from human bone marrow was
performed using the magnetic activated cell sorting
(MACS) system (Miltenyi Biotec, San Diego, CA) prior
to isolation of CD34+ subsets by flow cytometry. Bone
marrow CD34 selected cells were incubated with a cock-
tail of antibodies as well as FITC-labeled lineage deple-
tion antibodies (Additional file 2: Table S3). CD19 was
not included in the lineage depletion cocktail used for
sorting the progenitor B population. The immunopheno-
typic definitions used to isolate progenitors from human
bone marrow CD34 selected cells are described in
Additional file 2: Table S3. All populations were purified
using fluorescence-activated cell sorting on a FACSAria
(355, 405, 488, 561 and 633 nm lasers) (BD Immunocyto-
metry Systems).
Additional files
Additional file 1: Figure S1. BALR-6 locus encodes numerous
alternative splice forms. Figure S2. Knockdown and overexpression of full
length BALR-6 isoforms in mammalian cell lines. Figure S3. Constitutive
expression of BALR-6 in mice periphery. Figure S4. Elevated levels of
immature B cell populations in mice with BALR-6 overexpression. Figure
S5. SP1 targets in siRNA mediated knockdown cell lines. Figure S6.
Confirmation of global differential expression findings seen in initial
microarray. (PDF 1.19 mb)
Additional file 2: Tables S1. Primers and RACE sequences for BALR-6.
Table S2. Antibodies used for bone marrow transplant flow cytometry
analysis, and population gating schematics. Tables S3. Antibodies used
for CD34 enrichment of human bone marrow flow cytometry analysis,
and population gating schematics. (PDF 125 kb)
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